Price$186.76+56.49 (+43.36%)
2026-04-142026-07-17
News · 26 weeks92-67%
2026-01-252026-07-19
Mix4390d
- Insider23(53%)
- Other8(19%)
- Analyst4(9%)
- SEC Filings3(7%)
- Leadership3(7%)
- Earnings2(5%)
Latest news
25 items- PRIllumina expands Billion Cell Atlas program with new AI drug developersPartners will use unprecedented data scale to advance more precise medicines to approvalSAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics. "We are building the cell atlas to address key bottlenecks across the drug discovery and development continuum," said Rami Mehio, senior vice president and
- PRIllumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's we
- PRIllumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal OfficerNew leaders bring extensive leadership experience across life sciences, diagnostics, and medical technologySAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world."We are excited to welcome Mike and Julie to Illumina," said Jacob Thaysen, chief executive officer of Illumina. "Mik
- INSIDERDirector Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- ANALYSTBernstein resumed coverage on Illumina with a new price targetBernstein resumed coverage of Illumina with a rating of Mkt Perform and set a new price target of $185.00
- INSIDERChief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Skovronsky Daniel was granted 1,674 shares (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERSEC Form 3 filed by new insider Skovronsky Daniel3 - ILLUMINA, INC. (0001110803) (Issuer)
- SECIllumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
- PRDaniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of DirectorsEli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's BoardSAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms. "Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare
- PRIQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief ScientistCiesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a me
- ANALYSTIllumina upgraded by Analyst with a new price targetAnalyst upgraded Illumina from Neutral to Overweight and set a new price target of $185.00
- INSIDERSVP, Chief People Officer Leckman Patricia sold $127,305 worth of shares (783 units at $162.59), decreasing direct ownership by 4% to 21,259 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- PRIllumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solutionStrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundariesWhole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologiesSAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights. Spatial transcriptomics is al
- INSIDERSVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERChief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERVP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- PRIntegrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster InsightsIntegrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysis DRAGEN™ pipelines optimized for IDT custom hybrid capture panels enable accurate, efficient, variant detection The DRAGEN Somatic for IDT Custom Panels feature a new, low-quality FFPE mode to analyze challenging samples Integrated DNA Technologies (IDT), a Danaher company and global leader in genomics, today announced a strategic collaboration with Illumina, Inc. (NASDAQ:ILMN) to enable a DRAGEN™ secondary analysis pipeline for IDT xGen™ FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an
- INSIDERAmendment: SEC Form 4 filed by Director Meister Keith A.4/A - ILLUMINA, INC. (0001110803) (Issuer)
- PRIllumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology researchAutomating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panelsSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to acc
- PRIllumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD researchAn advanced research workflow for fast, flexible detection of molecular residual disease during and following treatmentSolution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD marketSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer
- SECIllumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
- INSIDERDirector King David P was granted 2,072 shares (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
ILMN FAQ
7 questionsWhat does Illumina Inc. do?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic...Where does ILMN stock trade?
Illumina Inc. (ILMN) is listed on NASDAQ.What sector and industry is ILMN in?
Illumina Inc. operates in the Health Care sector, Medical Specialities industry.When did Illumina Inc. go public?
Illumina Inc. (ILMN) completed its IPO in 2000.What are analysts saying about ILMN?
Illumina Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Mkt Perform on 2026-06-26.What companies are similar to ILMN?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), QGEN (Qiagen N.V.), TXG (10x Genomics Inc.). Compare ILMN side-by-side with any of them on Quantisnow.How can I track ILMN on Quantisnow?
Quantisnow aggregates Illumina Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ILMN to receive live email and push alerts on every new disclosure.